Your browser doesn't support javascript.
loading
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah, Eman; Reichert, Zachery R; Davenport, Matthew S; Chinnaiyan, Arul M; Dadhania, Vipulkumar; Wang, Xiaoming; Mannan, Rahul; Kunju, Lakshmi P; Hollenbeck, Brent K; Montgomery, Jeffrey S; Kaffenberger, Samuel D; Morgan, Todd M; Alva, Ajjai S; Palapattu, Ganesh S; Vaishampayan, Ulka N; Alumkal, Joshi J; Spratt, Daniel E; Udager, Aaron M; Mehra, Rohit.
Affiliation
  • Abdulfatah E; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Reichert ZR; Department of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Davenport MS; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Chinnaiyan AM; Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Dadhania V; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Wang X; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Mannan R; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
  • Kunju LP; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
  • Hollenbeck BK; Howard Hughes Medical Institute, Ann Arbor, MI, USA.
  • Montgomery JS; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Kaffenberger SD; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Morgan TM; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
  • Alva AS; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Palapattu GS; Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
  • Vaishampayan UN; Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, USA.
  • Alumkal JJ; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Spratt DE; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Udager AM; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Mehra R; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Med Oncol ; 38(3): 26, 2021 Feb 14.
Article in En | MEDLINE | ID: mdl-33586037
ABSTRACT
Neuroendocrine transdifferentiation of high-grade prostate cancer (PCA-NT) comprises a morphologic and immunophenotypic transition from conventional adenocarcinoma towards high-grade neuroendocrine/small cell carcinoma. This phenomenon is frequently observed post androgen deprivation and/or radiotherapy, but de novo instances are increasingly recognized. Herein, we report a series of de novo PCA-NT focusing on characteristic morphologic, immunophenotypic and clinical features. Treatment naïve PCA-NT were identified. IHC for PSA, NKX3.1, Chromogranin, Synaptophysin, Cyclin D1, RB and Ki67 were performed. Radiology, treatment and follow-up data were reviewed. Sixteen patients were included. Apart from focal areas of high-grade prostate cancer with acinar features (reminiscent of Grade Group 5 disease), extensive areas with sheets of cells with deep amphophilic/basophilic cytoplasm, enlarged, hyperchromatic nuclei with granular chromatin and inconspicuous to prominent nucleoli with high mitotic activity were identified. Immunohistochemistry showed patchy NKX3.1, patchy PSA, variable Synaptophysin and Chromogranin; RB and CyclinD1 showed loss of expression. Ki67 showed high proliferative index, in most cases. Adverse radiologic findings and metastases were documented in most cases. Two patients died of disease. De novo PCA-NT exhibits high-grade nuclei, high mitotic activity, reduced PSA expression with high Ki67 and functional inactivation of RB1 pathway, suggesting transition from androgen-driven to proliferation-driven phenotype. Most cases presented at advanced stage with adverse radiological findings, metastasis at time of diagnosis, and high mortality. In light of their prognostic and therapeutic implications, pathologists may need to maintain a sensitive threshold for performing immunostains-in particular, Ki67 and CyclinD1-when presented with such cases in their day to day clinical practice.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Biomarkers, Tumor / Cell Transdifferentiation / Neuroendocrine Cells Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Biomarkers, Tumor / Cell Transdifferentiation / Neuroendocrine Cells Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country:
...